GENESIS-PHARMA
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Named on the 2025 Global Cleantech 10015.1.2025 17:01:00 CET | Press release
2025: The Year We Remember the Guardrails Coming Off Coolbrook, a transformational technology and engineering company, has been named on Cleantech Groups 2025 Global Cleantech 100. This annual list, now in its 16th year, showcases the most promising private cleantech companies making significant contributions to sustainable innovation. The complimentary report will introduce you to innovators advancing groundbreaking technologies and business models to enable us to act on the ever-increasing climate and environmental crisis. The cleantech theme is poised for pivotal milestones in 2025 as market forces intensify and innovation accelerates. Continuing trends from 2024, including policy uncertainty, groundbreaking first-of-a-kind (FOAK) projects, and the surging demand for climate adaptation technologies, will emphasize the importance of product and project economics. Companies that capitalize on organic demand—such as the growing needs of data centers—and prove their technologies in real
Tecnotree Recognized in the 2024 Gartner® Hype Cycle™ for Customer Experience and Monetization in the Communications Industry15.1.2025 15:57:00 CET | Press release
Tecnotree, a global leader in digital Business Support System (BSS) provider and a transformation solution, is thrilled to announce its inclusion in the 2024 Gartner Hype Cycle for Customer Experience and Monetization in the Communications Industry. We believe, this acknowledgment highlights Tecnotree’s pioneering role in delivering Partner Ecosystem Management Platforms, AI for CSP Customer Interactions, and CSP Digital Marketplaces. The Gartner Hype Cycle serves as a trusted guide for evaluating the maturity and adoption of transformative technologies in the communications sector. In our opinion. Tecnotree’s recognition underscores its ability to enable Communication Service Providers (CSPs) to streamline operations, create innovative revenue opportunities, and deliver hyper-personalized customer experiences. Tecnotree’s Partner Ecosystem Management Platforms empower CSPs to seamlessly onboard, integrate, and manage diverse partners, unlocking new revenue streams through collaborativ
Fluence Wins Cultivation Technology of the Year at 2024 Emjays15.1.2025 15:00:00 CET | Press release
Fluence was awarded Lighting Company of the Year at the Emjays’ inaugural program in 2023 Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis production, won back-to-back Emjays International Cannabis Awards, taking home Cultivation Technology of the Year during MJBizCon 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115876512/en/ Fluence wins Cultivation Technology of the Year at the Emjays International Cannabis Awards during MJBizCon 2024 (photo courtesy of the Emjays) The Emjays is a collaboration between award-winning event producers Farechild Events and MJBizCon, the cannabis industry’s largest trade show and media entity. The program is dedicated to recognizing leaders and innovators in more than 20 ancillary business categories within the cannabis industry. Fluence was named Lighting Company of the Year at the program’s inaugural event in 2023. “As the global
BlueFlag Security Named an IDC Innovator for Software Development Life-Cycle Identity and Access15.1.2025 15:00:00 CET | Press release
One of only three vendors included in the report, the BlueFlag platform provides a unified, context-rich, and identity centric view of risks across all key SDLC attack vectors including developer identities, toolchains, and code BlueFlag Security, a leader in software development lifecycle (SDLC) security and governance, is proud to be named an IDC Innovator in the report, IDC Innovators: Software Development Life-Cycle Identity and Access, 2024 (Doc # US52748124, December 2024). IDC Innovator reports recognize emerging vendors offering innovative new technology that alleviates challenges facing IT and security buyers. The IDC Innovators report noted, “SDLC identity and access solutions reduce the risk of credential compromise, unauthorized access, and lateral movement within development environments. They play a critical role in safeguarding the software supply chain by ensuring only legitimate identities can interact with sensitive systems and data.” The report shared about BlueFlag
Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights15.1.2025 15:00:00 CET | Press release
New reports bring key financial insights and market comparisons to directors, CFOs, general counsel and executives, giving clarity into investor risks. Diligent, a leading GRC SaaS company, today announced it is collaborating with S&P Global’s Market Intelligence division to launch Diligent Market Insights Reporting. Powered by S&P Capital IQ Pro data, the reports give corporate directors and executives timely, contextualized insights into global financial data and peer performance – including market sentiment, analyst consensus, peer developments and industry analysis – to stay ahead of market and investor risks. The reports are built within the Diligent One Platform, Diligent’s leading GRC platform empowering more than 1 million users and 700,000 board members and leaders to make better decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115272711/en/ (Graphic: Business Wire) “Today’s corporate directors are navig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom